|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||An 18 amino acid peptide from near the amino terminus of human BRCC36.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Immunohistochemistry (IHC)||2.5 µg/ml|
|Western Blot (WB)||0.5-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
A suggested positive control is MCF7 cell lysate.
PA5-20426 can be used with blocking peptide PEP-0543.
Together with the breast and ovarian predisposition proteins BRCA1 and BRCA2 and RAD51 and BRCC45, BRCC36 forms a holoenzyme complex that possesses a ubiquitin E3 ligase activity. Aberrant levels of BRCC36 were detected in sporadic breast tumors and depletion of either BRCC36 or BRCC45 by siRNA resulted in increased sensitivity to ionizing radiation and defects in the G2/M checkpoint, indicating that BRCC36 acts to enhance cellular survival following DNA damage. Recent experiments have shown that BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation, suggesting that BRCC36 may be an important target in the treatment of radiation-resistant breast tumors. At least two isoforms of BRCC36 are known to exist.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro.
PA5-20426 was used in immunohistochemistry - paraffin section and western blot to study the role of BRCC3 in nasopharyngeal carcinoma prognosis and radiosensitivity
|Tu Z,Xu B,Qu C,Tao Y,Chen C,Hua W,Feng G,Chang H,Liu Z,Li G,Jiang C,Yi W,Zeng M,Xia Y||Radiation oncology (London, England) (10:null)||2015|